Replies to post #186712 on Biotech Values

[north40000]

I wonder whether the once-projected price war between the HCV treatment purveyors has not in fact started and now is near full blown via the instigation of, and exclusive contracts with, PBMs. The result approaches UK system on nearly a daily basis with every new contract announced based on discounted price of treatment medium.

I have trouble reconciling the relatively low prices charged by GILD and ABBV for their relative cures of HCV in a short time with the treatment prices allowed orphan drug purveyors for daily treatment of chronic diseases often for a life time of years.

Once again, the bean counters at the insurance companies and their PBMs never saw a cure of HCV coming, and had no reserves available to permit cures w/o a discounted price.

[DewDiligence]

You had a typo in #msg-110345018 that might be confusing some people:

…about half of patients don't know they are HCV-positive, whereas all the patients in the [Ryan White] program know their HCV status…

The second reference to “HCV” should be “HIV”.

I concur with the overall assessment in your bottommost paragraph.

[dewophile]

edit - i made an error in my calculation. of the 150K HIV pts getting treatment about 25% are HCV positive so the potential market is 38K pts which equates to 3.8M covered lives based on a 1% prevalence